Literature DB >> 9234508

Bacteriophage therapy and prophylaxis: rediscovery and renewed assessment of potential.

P A Barrow1, J S Soothill.   

Abstract

Bacteriophages were discovered 82 years ago. Claims for their use in the treatment of infections were not confirmed by early controlled trials, and the success of antibiotics superseded this potential use. However, recent studies have shown interesting therapeutic effects that warrant further investigation and development.

Entities:  

Mesh：

Substances：

Year:  1997        PMID： 9234508     DOI： 10.1016/S0966-842X(97)01054-8

Source DB:  PubMed          Journal:  Trends Microbiol        ISSN： 0966-842X            Impact factor:   17.079


  63 in total

1.  The murky origin of Snow White and her T-even dwarfs.

Authors:  S T Abedon
Journal:  Genetics       Date:  2000-06       Impact factor: 4.562

Review 2.  Bacteriophage therapy.

Authors:  A Sulakvelidze; Z Alavidze; J G Morris
Journal:  Antimicrob Agents Chemother       Date:  2001-03       Impact factor: 5.191

3.  MM1, a temperate bacteriophage of the type 23F Spanish/USA multiresistant epidemic clone of Streptococcus pneumoniae: structural analysis of the site-specific integration system.

Authors:  E Gindreau; R López; P García
Journal:  J Virol       Date:  2000-09       Impact factor: 5.103

Review 4.  Pharmacokinetic principles of bacteriophage therapy.

Authors:  Robert J H Payne; Vincent A A Jansen
Journal:  Clin Pharmacokinet       Date:  2003       Impact factor: 6.447

5.  Selection and characterization of a multivalent Salmonella phage and its production in a nonpathogenic Escherichia coli strain.

Authors:  S B Santos; E Fernandes; C M Carvalho; S Sillankorva; V N Krylov; E A Pleteneva; O V Shaburova; A Nicolau; E C Ferreira; J Azeredo
Journal:  Appl Environ Microbiol       Date:  2010-09-03       Impact factor: 4.792

6.  Efficacy of bacteriophage therapy against gut-derived sepsis caused by Pseudomonas aeruginosa in mice.

Authors:  Ryohei Watanabe; Tetsuya Matsumoto; Go Sano; Yoshikazu Ishii; Kazuhiro Tateda; Yoshinobu Sumiyama; Jumpei Uchiyama; Shingo Sakurai; Shigenobu Matsuzaki; Shosuke Imai; Keizo Yamaguchi
Journal:  Antimicrob Agents Chemother       Date:  2006-11-20       Impact factor: 5.191

7.  Efficacy and pharmacokinetics of bacteriophage therapy in treatment of subclinical Staphylococcus aureus mastitis in lactating dairy cattle.

Authors:  J J Gill; J C Pacan; M E Carson; K E Leslie; M W Griffiths; P M Sabour
Journal:  Antimicrob Agents Chemother       Date:  2006-09       Impact factor: 5.191

8.  Phage as an antimicrobial agent: d'Herelle's heretical theories and their role in the decline of phage prophylaxis in the West.

Authors:  Dottore Emiliano Fruciano; Shawna Bourne
Journal:  Can J Infect Dis Med Microbiol       Date:  2007-01       Impact factor: 2.471

9.  Therapy of experimental pseudomonas infections with a nonreplicating genetically modified phage.

Authors:  Steven Hagens; André Habel; Uwe von Ahsen; Alexander von Gabain; Udo Bläsi
Journal:  Antimicrob Agents Chemother       Date:  2004-10       Impact factor: 5.191

10.  Isolation and characterization of a virulent bacteriophage AB1 of Acinetobacter baumannii.

Authors:  Hongjiang Yang; Li Liang; Shuxiang Lin; Shiru Jia
Journal:  BMC Microbiol       Date:  2010-04-29       Impact factor: 3.605
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.